TransMedics (TMDX) Cost of Revenue (2018 - 2026)

TransMedics' Cost of Revenue history runs 9 years deep, the most recent figure standing at $72.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 31.57% year-over-year to $72.8 million in Q1 2026; TTM through Mar 2026 was $260.2 million, a 31.47% increase from a year earlier, with the FY2025 full-year figure at $242.7 million, up 35.23% from the prior year.
• Cost of Revenue improved to $72.8 million in Q1 2026 per TMDX's latest filing, from $67.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $72.8 million in Q1 2026 and bottomed at $3.8 million in Q1 2022.
• The 5-year median for Cost of Revenue is $36.9 million (2024), against an average of $35.9 million.
• Across the five-year window, Cost of Revenue soared 373.89% in 2022 and climbed 23.65% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $10.7 million in 2022, then jumped by 211.56% to $33.2 million in 2023, then surged by 49.21% to $49.6 million in 2024, then soared by 35.76% to $67.4 million in 2025, then climbed by 8.05% to $72.8 million in 2026.
• Per Business Quant, the three latest TMDX Cost of Revenue figures stand at $72.8 million (Q1 2026), $67.4 million (Q4 2025), and $59.2 million (Q3 2025).